Kura Oncology (KURA) Stock Price, News & Analysis

Company Overview

Kura Oncology, Inc. is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.

Kura’s leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements. The company has also developed tipifarnib, a farnesyl transferase inhibitor investigated in several cancer indications, including diseases involving HRAS mutations.

Founded in 2014 and headquartered in San Diego, California, Kura has conducted clinical development activities through collaborations with academic institutions, research organizations and pharmaceutical companies. Its operations and clinical programs have been directed primarily toward patients and healthcare markets in the United States and other international regions where its investigational therapies are studied.

Key Stats

• Today's Range: $10.83 to $11.81
• 50-Day Range: $8.93 to $13.59
• 52-Week Range: $7.36 to $13.90
• Volume: 2.77 million shs
• Average Volume: 1.67 million shs
• Market Capitalization: $982.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.40
• Consensus Rating: Moderate Buy

Kura Oncology Stock Analysis - MarketRank™

Kura Oncology scored higher than 68% of companies evaluated by MarketBeat, and ranked 222nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Kura Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 10 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Kura Oncology has a consensus price target of $25.40, representing about 129.9% upside from its current price of $11.05.

Amount of Analyst Coverage

Kura Oncology has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Kura Oncology are expected to grow in the coming year, from ($3.25) to ($2.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kura Oncology is -3.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kura Oncology is -3.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kura Oncology has a P/B Ratio of 5.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.32% of the float of Kura Oncology has been sold short.

Short Interest Ratio / Days to Cover

Kura Oncology has a short interest ratio ("days to cover") of 4.79.

Change versus previous month

Short interest in Kura Oncology has recently increased by 2.23%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kura Oncology does not currently pay a dividend.

Dividend Growth

Kura Oncology does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.55

News Sentiment

Kura Oncology has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Kura Oncology this week, compared to 7 articles on an average week.

Search Interest

9 people have searched for KURA on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.

MarketBeat Follows

4 people have added Kura Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 3.1 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $1,901,657.00 in company stock, which represents 0.1935% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Kura Oncology insiders have bought 423.21% more of their company's stock than they have sold. Specifically, they have bought $2,351,000.00 in company stock and sold $449,343.00 in company stock.

Percentage Held by Insiders

7.60% of the stock of Kura Oncology is held by insiders.

Percentage Held by Institutions

Kura Oncology has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/23/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KURA
• CIK: 1422143
• Web: www.kuraoncology.com
• Phone: (858) 500-8800
• Fax: N/A
• Employees: 260
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Kura Oncology: $25.40
• High Price Target: $40.00
• Low Price Target: $15.00
• Potential Upside/Downside: +130.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$278.67 million
• Net Margins: -384.30%
• Pretax Margin: -384.19%
• Return on Equity: -207.18%
• Return on Assets: -45.17%

Debt

• Debt-to-Equity Ratio: 0.12
• Current Ratio: 4.73
• Quick Ratio: 4.71

Sales & Book Value

• Annual Sales: $67.48 million
• Price / Sales: 14.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.00 per share
• Price / Book: 5.52

Miscellaneous

• Outstanding Shares: 88,960,000
• Free Float: 82,200,000
• Market Cap: $982.12 million
• Optionable: Optionable
• Beta: 0.44